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ABSTRACT
Current guidelines for treatment decision making largely rely on data from randomized controlled trials
(RCTs) studying average treatment effects. They may be inadequate to make individualized treatment
decisions in real-world settings. Large-scale electronic health records (EHR) provide opportunities to fulfill
the goals of personalized medicine and learn individualized treatment rules (ITRs) depending on patient-
specific characteristics from real-world patient data. In this work, we tackle challenges with EHRs and
propose a machine learning approach based on matching (M-learning) to estimate optimal ITRs from EHRs.
This new learning method performs matching instead of inverse probability weighting as commonly used
in many existing methods for estimating ITRs to more accurately assess individuals’ treatment responses
to alternative treatments and alleviate confounding. Matching-based value functions are proposed to
compare matched pairs under a unified framework, where various types of outcomes for measuring
treatment response (including continuous, ordinal, and discrete outcomes) can easily be accommodated.
We establish the Fisher consistency and convergence rate of M-learning. Through extensive simulation
studies, we show that M-learning outperforms existing methods when propensity scores are misspecified
or when unmeasured confounders are present in certain scenarios. Lastly, we apply M-learning to estimate
optimal personalized second-line treatments for type 2 diabetes patients to achieve better glycemic control
or reduce major complications using EHRs from New York Presbyterian Hospital. Supplementary materials











Personalized medicine calls for a paradigm shift from the uni-
versal strategy that assigns the same treatment to all patients
affected by a disorder to selecting treatment strategies that opti-
mize individual patient’s health outcomes according to individ-
ual characteristics (Collins and Varmus 2015). Improvements
in technologies for collecting personal data, accompanied with
developments of machine learning and statistical methods to
analyze these data, hold promise to enable health-care providers
to prescribe the right therapy to the right patient at the right time
(Collins and Varmus 2015; Chakraborty and Moodie 2013).
By treating each patient with the optimal individualized treat-
ment, patients can potentially gain enhanced clinical benefits,
experience less side effects, and be more adherent to treatments
(Chakraborty and Moodie 2013).
Machine learning approaches provide valuable tools to esti-
mate individualized treatment rules (ITRs) and dynamic treat-
ment rules (DTRs) due to their powerful computing capabilities.
Previously proposed machine learning approaches include Q-
learning (Watkins and Dayan 1992; Qian and Murphy 2011),
outcome weighted learning (O-learning) (Zhao et al. 2012),
boosting-based treatment selection (Kang, Janes, and Huang
2014), augmented O-learning (Liu et al. 2018, AOL), and sub-
group identification methods (Fu, Zhou, and Faries 2016). Most
of these existing methods focus on analyzing randomized clin-
ical trial (RCT) data. However, the ITRs estimated from ran-
domized controlled trials (RCTs) may be inadequate to assist
individualized treatment decision making in real-world settings
due to stringent inclusion/exclusion criteria of RCTs, a lack of
generalizability, and a lack of evidence for long-term outcomes.
Large-scale electronic health records (EHRs) provide new
opportunities to learn ITRs using real-world patient data. In
recent years, access to clinical data warehouses and databases
continues to grow and an increasing trend of using EHRs for
scientific research is observed (Weiskopf and Weng 2013; Hripc-
sak and Albers 2013; Hripcsak et al. 2016). As exclusive evi-
dence generated from clinical trials is inadequate due to a lack
of external validity, EHRs can serve as an important comple-
ment to evidence-based research for personalized medicine. For
instance, a broad range of real-world medication use patterns
not captured by RCTs were observed in EHRs (Hripcsak et al.
2016). Furthermore, as compared to RCTs, using EHRs to learn
ITRs has benefits such as containing information on a large pop-
ulation over relatively longer time frames that reflects patients’
care management and disease course in more realistic settings.
However, EHRs are not collected for research purposes and
conducting research with EHRs encounters great challenges.
Critical issues including confounding bias and selection bias
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have been discussed (Hripcsak and Albers 2013; Haneuse 2016).
In the context of estimating ITRs, common practice to adjust for
confounding is inverse probability weighting (IPW) of propen-
sity scores. The IPW approach requires a sophisticated model to
estimate propensity scores with high accuracy. Machine learn-
ing methods are thus proposed to predict propensity scores (Lee,
Lessler, and Stuart 2010, 2011; Austin and Stuart 2015), but they
may result in extreme weights with high variability. In addition,
the IPW approaches may not adequately balance covariate dis-
tributions between treatment groups, especially when the distri-
bution of propensity scores has less overlap between treatment
arms (Crump et al. 2009).
On the other hand, matching has been successfully used
to estimate population average treatment effects, including
ratio matching (Smith 1997), nearest neighbor matching
(Dehejia and Wahba 1999), and full matching (Stuart 2010;
Hansen 2004). However, to the best of our knowledge, there
is no method to leverage advantages of matching to estimate
personalized treatment rules and apply to observational data
such as EHRs. In this article, we propose a machine learning
approach, namely matched Learning (M-learning), to estimate
ITRs through matching treated and untreated subjects with
an application to EHRs. M-learning is a general framework
that includes O-learning and AOL as special cases. M-learning
introduces matching-based value function to match individual
treatment responses under alternative treatments and alleviate
confounding. Under a unified framework, an appropriate
matching function can be used to compare outcomes for
matched pairs to accommodate different types of data for mea-
suring treatment response (continuous, discrete, or ordinal).
The efficiency of M-learning can be improved by a de-noise
procedure and doubly robust matching. The implementation
is based on a matched-pairs weighted support vector machine.
We establish the Fisher consistency and convergence rate of
M-learning and conduct extensive simulation studies. We show
that M-learning outperforms existing methods when propensity
scores are misspecified and in certain scenarios when unmea-
sured confounders are present. Lastly, we tackle challenges of
EHRs (e.g., confounding by indication, confounding bias, and
selection bias) and apply M-learning to estimate the optimal
second-line treatments for type 2 diabetes (T2D) patients to
achieve better glycemic control or reduce major complications
using EHRs from New York Presbyterian Hospital.
2. Methodology
2.1. Individualized Treatment Rules
Let Hi denote the pretreatment covariates and let Ai denote
the binary treatment assignment taking values from {−1, 1}.
Let Ri denote the clinical outcome posttreatment (reward), and
assume a larger Ri is more desirable (e.g., symptom reduction).
An ITR is a decision rule, D(Hi), that maps the domain of Hi to
the treatment choices in {−1, 1}. The value function associated
with D used to evaluate an ITR is defined as the expected
posttreatment outcome by followingD to assign treatments, that
is, V(D) = ED(Ri).
For RCTs, the assumption that the potential outcomes are
independent of treatment assignment given covariates is sat-
isfied, and the treatment assignment probability, denoted by
π(a, h) = Pr(Ai = a|Hi = h), is known by design. O-






, and then aims to maximize the empiri-







In an observational study, however, treatment propensities
π(Ai, Hi) are unknown and need to be estimated from data.
Using the objective function (1) and IPW-based methods in
observational studies suffer from instability and increased
variance, especially when weights are highly variable. In
addition, IPW-based methods do not directly control the
balance of covariate distributions between treatment groups.
2.2. Matched Learning (M-learning)
When comparing different treatment responses, matching
methods can be designed to ensure balanced distribution at
subgroup level and provide more flexible tools to control the
matching quality of important confounders in subgroups or
even on individual subjects. For example, covariates selection,
distance metric and measure of covariates balance can be
combined to optimize matching (Sekhon and Grieve 2012)
and identify matching subjects to guarantee numerical stability,
especially when some subgroup of patients rarely receive one
particular treatment. Denote the matched set for subject i as
Mi, which consists of subjects with opposite treatments but
similar covariates as subject i, where similarity is defined under
a suitable distance metric. That is, we let
Mi =
{
j : Aj = −Ai, d(Hj, Hi) ≤ δi
}
,
where d(·, ·) is a metric defined in the covariate space and δi is
a prespecified positive threshold to determine the size of the
matched set which may vary across subjects. For example, if
we choose Mi to be the nearest neighbor, then δi is the mini-
mal distance between subject i and any other subject with the
opposite treatment. In some applications, subjects with empty
matching sets may be excluded. In this article, we use nearest
neighbor in the matching step of M-learning in the simulations
and application, and study its theoretical properties.
M-learning is developed to maximize a matching-based
value function defined in Equation (2). The motivation of M-
learning is that when two subjects are matched in confounders
or propensity scores of treatments but are observed to receive
opposite treatments, the subject with a larger clinical outcome
should be more likely to have received the optimal treatment
among two options. Based on this rationale, one expects that if
j ∈ Mi and Rj ≥ Ri, then the optimal ITR for subject i should
more likely to be Aj, and vice versa. Furthermore, the likelihood
is expected to be greater if the difference between Rj and Ri is
larger. Specifically, for any given ITR D, define the matching-
based value function as







I(Rj ≥ Ri,D(Hi) = −Ai)
+I(Rj ≤ Ri,D(Hi) = Ai)
}
g(|Rj − Ri|), (2)
where |Mi| is the size of Mi and g(·) is a monotonically
increasing function specified by users to weight different pairs
of subjects. Typical choices of g(·) can be g(x) = 1 or g(x) = x.
Furthermore, let D(H) = sign(f (H)) for some ITR decision
function f , then the matching-based value function (2) is equiv-
alent to






I(f (Hi)Aisign(Rj − Ri) ≤ 0)
× g(|Rj − Ri|).







I(f (Hi)Aisign(Rj − Ri) ≥ 0)
× g(|Rj − Ri|), (3)
in order to identify the optimal ITR.
The objective function (3) can be further expanded by allow-
ing Mi = i (match subject i with himself/herself). If in addi-
tion we replace Rj in Equation (3) by zero (when Rj > 0 for
all subjects) or the smallest observed outcome when negative
outcomes are present and choose g(x) = x, M-learning reduces
to the original O-learning in Zhao et al. (2012). Similarly, if
we replace Rj by subject i’s predicted outcome estimated from
a parametric model including only the main effects of Hi, M-
learning reduces to the single-stage AOL in Liu et al. (2018).
Thus, O-learning and single-stage AOL are special cases of M-
learning, where they compare the observed outcome Ri with
a constant or the predicted outcome given Hi averaged across
treatments. In contrast, M-learning compares observed indi-
vidual outcomes from two subjects in the matched set, where
the treatment assignment is approximately “random” given Hi
but the received treatments are opposite. Thus, M-learning is
more informative in taking account of information on patient’s
outcome at the individual level (Ri and Rj), instead of comparing
a patient’s outcome with the predicted outcome averaged over
treatments (as done in O-learning or AOL).
Minimizing the matching-based value function (3) is not fea-
sible due to the discontinuity of the indicator function. Similar
to O-learning, we replace the zero-one loss by other surrogate
loss functions. In particular, when using the hinge-loss, the
objective function to be optimized is the loss function for the
weighted support vector machine (SVM) with matched pairs






φ(−f (Hi)Aisign(Rj − Ri))
×g(|Rj − Ri|) + λn‖f ‖HK , (4)
where φ(x) = (1 − x)+, λn is a tuning parameter and HK is a
reproducing kernel Hilbert space (RKHS) with kernel function
K(·, ·). The solution to M-learning is obtained by minimizing
Vn,φ(f ; g). In terms of implementation, the dual problem of
Equation (4) is a quadratic problem which can be solved by any
off-the-shelf quadratic programming packages.
Taking linear ITR decision rules as an example, we describe
solution to the quadratic programming problem using Lagrange
multipliers. Assume f in Vn,φ(f ; g) is linear and f (h) = 〈β , h〉 +
β0, where 〈·, ·〉 denotes the inner product operator and ‖f ‖HK
represents ‖f ‖2 in Euclidean space. It is computationally conve-










subject to Aisign(Ri − Rj)(〈β , Hi〉 + β0)
≥ (1 − ξij), ξij ≥ 0, ∀i and j ∈ Mi,
where ξij is a slack variable that represents misclassification error
for the jth subject in the matched set of the ith subject, C is a
cost parameter, and |Mi|−1g(|Rj−Ri|) is the individual-specific
weight in a weighted SVM framework.





















where we minimize with respect to β , β0 and ξij. By taking the
respective derivatives and setting them to zero to obtain,⎧⎪⎨⎪⎩
β = ∑ni=1 ∑j∈Mi αijAisign(Ri − Rj)Hi,
0 = ∑ni=1 ∑j∈Mi αijAisign(Ri − Rj),
αij = C|Mi|−1g(|Rj − Ri|) − μij, ∀i and j ∈ Mi.

















×sign(Ri − Rj)sign(Ri′ − Rj′)〈Hi, Hi′ 〉
subject to 0 ≤ αij ≤ C|Mi|−1g(|Rj − Ri|) and ∑ni=1 ∑j∈Mi
αijAisign(Ri − Rj) = 0. In addition, subject to Karush–Kuhn–
Tucker conditions for ∀i and j ∈ Mi (Zhao et al. 2012):⎧⎪⎨⎪⎩
αij[Aisign(Ri − Rj)(HTi β + β0) − (1 − ξij)] = 0,
μijξij = 0,
Aisign(Ri − Rj)(HTi β + β0) − (1 − ξij) ≥ 0,
the solution to the primal and dual problem is optimal. It is
straightforward to extend the algorithm to other kernels (e.g.,
Gaussian kernel) and obtain a nonparametric ITR based on
kernel function K(·, ·) in the RKHS.
2.3. Improved M-Learning
To improve the performance of M-learning, we use a de-noise
procedure first reported in Liu et al. (2018). We replace Ri by a
surrogate residualized outcome R̃i = Ri − s(Hi) in Vn(D; g) for
any measurable function of Hi, denoted as s(Hi). These resid-
ualized outcomes remove the main effects of covariates, which
improves efficiency of identifying tailoring variables exhibiting
quantitative or qualitative interaction with treatment. The resid-
uals can be obtained through a regression model and the value
function to be maximized becomes







I(̃Rj ≥ R̃i,D(Hi) = −Ai)
+I(̃Rj ≤ R̃i,D(Hi) = Ai)
}
g(|̃Rj − R̃i|).
As shown in Liu et al. (2018), by removing the main effects of
covariates, more stable weights are used in the weighted SVM to
boost efficiency in estimating ITRs.
Furthermore, prognostic scores can be incorporated into M-
learning under the framework of doubly robust matching esti-
mator (DRME) proposed in Antonelli et al. (2018). The DRME
uses both propensity scores and prognostic scores to construct a
matching set M(i, θ), where θ = (θ1, θ2)T denotes parameters
for the propensity score and prognostic score models:
π(H) = P(A = 1|H) = u1(HTθ1), m(H)
= E(R|A = −1, H) = u2(HTθ2). (5)
Antonelli et al. (2018) showed that only one of the two models in
Equation (5) is required to be correctly specified to ensure con-
sistency of DRME, which achieves double robustness. Applying
DRME to M-learning, both propensity scores and prognostic
scores will be included in the matching step to create informative
matched pairs. The doubly robust M-learning is consistent even
if one of the propensity score model or prognostic model is mis-
specified, and it will be more efficient than regular M-learning
if both models are correctly specified. Note that M-learning can
be applied to RCT data where only prognostic scores need to be
included in the matching step to improve efficiency.
3. Theoretical Properties
In this section, we establish the theoretical properties including
Fisher consistency, different choices of g(x) and convergence
rate of M-learning.
3.1. Fisher Consistency
Theorem 3.1. Under regularity assumptions including maxni=1 δi→ 0, and that the density of H and E[R|H, A = 1] is continu-
ously differentiable in the support of H, it holds that
Vn(f , g) →a.s V(f , g),
where




I(f (H)Asign(̃R − R) ≤ 0)
×g(|̃R − R|)
∣∣∣Ã = −A, H̃ = H]},
where Ẽ is the expectation with respect to (̃R, H̃, Ã), an indepen-
dent copy of (R, H, A). In addition, define

g(r, h) = E
[
g(|R − r|)





|R − r| (R − r)|A = −1, H = h
]
,
then for any h in the support of H,




g(r, h)dF(r|H = h),
where F(r|H = h) is the distribution of R = r given H = h and
f ∗ is the optimal function minimizing V(f ; g).
The proof of Theorem 3.1 is given in the appendix. Here we
make a few remarks.
Remark 1. When g(x) = x and r = 0, that is, 
g(r, h) =
E(R|A = 1, H = h) − E(R|A = −1, H = h), Theorem
3.1 implies that the optimal treatment rule obtained from M-
learning is the same as the optimal rule from O-learning, and
thus M-learning is Fisher consistent for the usual optimal ITR.
Remark 2. When g(x) = 1, we obtain

g(r, h) = E
[
sign(R − r)|A = 1, H = h]
−E [sign(R − r)|A = −1, H = h]
= 2[P(R > r|A = 1, H = h)
−P(R > r|A = −1, H = h)].
Remark 2 suggests that for subjects with H = h, the optimal
rule chooses the treatment with a higher probability of having
a greater outcome than the average outcome across treatments.
Such choice of g(x) ensures robustness against outliers of R.
When R is an ordinal or binary random variable, this choice is
especially suitable. For example, consider an ordinal outcome
with three levels, then the optimal rule f ∗(h) has a desirable
property
sign(f ∗(h)) = sign[AUC13(h) − AUC23(h)], (6)
where AUCjk(h) is the conditional AUC for comparing R = j
with R = k for subjects with H = h. More generally, the
function 
g(r, h) is similar to creating comparisons based on
a reference level r of the outcome. Therefore, for a particular
target value r (e.g., the value under a universal “one-size-fits-
all” treatment assignment, or a clinically meaningful level for
an ordinal outcome), one can construct g(x) so that the weights
concentrate on the difference from the reference value r.
Remark 3. Lastly, when applied to observational studies, the
condition of no unmeasured confounders ensures that the opti-
mal rule estimates the treatment with a higher potential out-
come, since 
g(r, h) = E(R(1)|H = h) − E(R(−1)|H = h),
where R(k) denotes the potential outcome under treatment k.
3.2. Convergence Rate of M-Learning
In this section, we establish the convergence rate of the risk
bound for the estimated decision rule. We consider the nearest
neighborhood matching, HK is the RKHS based on a Gaussian
kernel function with bandwidth σn, and assume R and H are
bounded. Furthermore, we need the following assumptions:
(A.1) The density of H = h with respect to the dominating
measure and E(R|A = a, H = h) are continuously differentiable
in H’s support for a = −1 and 1. Moreover, the density of H is
bounded from below on the support of H, denoted by XH .
(A.2) The probability measure has a geometric noise exponent
α > 0 as in Definition 2.3 of Steinwart and Scovel (2007). That
is, if let τH be the distance from any H to the decision boundary
{h : f ∗(h) = 0}, it holds
E[|f ∗(H)| exp{−τ 2H/t}] ≤ ctαd/2, t > 0.
(A.3) There exists γ > 0 and r0 > 0 such that |XH ∩ B(h, r)| ≥
γ |B(h, r)| for any h ∈ XH and 0 < r < r0, where B(h, r) is a ball
centered at h with radius r, and |A| denotes the volume of set A
in XH .
Condition (A.1) is necessary to ensure the consistency of
approximation in the nearest-neighbor based matching. Con-
dition (A.2) is commonly assumed for SVMs and a similar
condition has been considered for classification problem (see
Steinwart and Scovel 2007) and establishing the learning rate for
ITRs (Zhao et al. 2012). When the decision rule is completely
separable, the exponent α can be as large as possible. The
third condition (A.3) is used to obtain the convergence for the
nearest-neighbor estimator (Devroye, Györfi, and Lugosi 2013)
Theorem 3.2. Under the above assumptions and letting σn =
λ
1/p(1+α)
n , it holds














where β1 = p/4+ (1/2−p/8)d/[(1 +α)], β2 = 1/2p(1 +α)+
1/2, and mn is the size of the nearest neighbor.
The proof of Theorem 3.2 is given in the appendix. Note that
the convergence rate will depend on the dimension, the geo-
metric noise exponent α and the choice of tuning parameter σn.
Moreover, we observe that when λn = n−θ with a constant θ and
the size of nearest-neighbor equals to n2/(p+2), the polynomial
convergence rate can be attained.
4. Simulation Studies
We conducted extensive simulation studies to compare M-
learning with Q-learning and single-stage AOL as improved
O-learning Liu et al. (2018). Data were simulated under
an observational study design where treatment assignment
depends on pretreatment variables H. Simulation settings and
analyses we considered include: (1) No unmeasured confounder
and the propensity score model given H is correctly specified in
the analyses; (2) No unmeasured confounder but the propensity
score model is misspecified; and (3) Unmeasured confounders
are present and some components of H are not observed and
not included in the analyses.
In these simulations, one-to-one matching with replacement
was used and features were matched using the shortest
Euclidean distance function (one nearest-neighbor). The tuning
parameters for AOL and M-learning (including choice of
kernel as linear or Gaussian, inverse radius, and cost C) were
selected by three-fold cross validation. The value function
corresponding to the estimated optimal rule was computed on
a large independent testing set with a sample size of 10,000
using empirical average. Q-learning was fit with a linear model
including feature variables and their interaction with treatment
as covariates. We varied sample size of training data from 100
to 1000 and repeated the simulations 100 times.
We first considered continuous responses in two settings:
S1 : R = 2H3 − H4 + A(H1 − H2) + 6sign(H1) + N(0, 1)
and
S2 : R = 1 + 2H1 + H2 + 0.5H3 + A(H2 + H21 − 1)
+6sign(H1) + N(0, 1).
Uncorrelated feature variables Hk with standard normal dis-
tributions were simulated. Since heterogeneity and clustering
effects are observed in the real-world patient population (e.g.,
Figure A3.2 of NYPH EHRs in supplementary materials), we
considered the distribution of reward outcomes to be clustered
in strata depending on the first feature variable H1. The true
optimal treatment decision boundary is linear in setting S1, and
nonlinear in setting S2. The true optimal value is 1.20 in S1
and 2.29 in S2. In the continuous response scenario, g(x) = x
was used for M-learning. In setting S1 and S2, M-learning and
doubly robust M-learning by stratifying on prognostic scores
(referred to as “M-learning Stratified” in Figure 1 and 2) were
considered. For the latter, prognostic scores were obtained using
random forest. Prognostic factors used in the matching step
were created by dichotomizing the prognostic scores based on
the median split.
In the first set of simulations, distribution of A depends on
H and no unmeasured confounder is present. Clinical response
outcomes were simulated under setting S1 and S2, and the true
propensity model was specified as P(A = 1|H) = expit(1 +
2H1 + H2). In this case, H1 and H2 are observed confounders.
The propensity scores were estimated through a logistic regres-
sion model with treatment as binary outcome and features
H1, H2 as linear predictors. On average, 64% of subjects received
an active treatment and 36% received a control treatment. Sim-
ulation results are presented in the top panel of Figure 1. For
setting S1, Q-learning has the best performance since the linear
function is the true optimal treatment separation boundary.
Doubly robust M-learning performs similarly as Q-learning
with larger sample size. It is clear that doubly robust M-learning
improves efficiency. For S2 with a nonlinear boundary, both M-
learning and doubly robust M-learning achieve a higher empir-
ical value than AOL and Q-learning. In this case Q-learning and
AOL lose efficiency because they do not capture the information
in prognostic scores, even though the propensity scores were
consistently estimated.
In the second set of simulations, the true propensity score
model was specified as P(A = 1|H) = expit(1 + exp(H2)). The
propensity scores were estimated through a logistic regression
model with linear predictors, and thus the model was mis-
specified. On average, 88% of subjects received one treatment
and 12% received the other. Simulation results are presented
in the bottom panel of Figure 1. In both setting S1 and S2, the
results suggest that M-learning is more robust to misspecified
propensity model compared to Q-learning and O-learning. The
best performance is achieved by the doubly robust M-learning,
where the estimated value function is very close to the true
optimal value with a large sample size. Matching using prog-
nostic scores in doubly robust M-learning has protected against
Figure 1. Value comparison of four methods with propensity scores correctly specified (top panel) and misspecified (bottom panel). The numbers at the top of each
subfigure are mean values.
deteriorated performance when the propensity score model is
misspecified.
In the third set of simulations, we considered presence of
unmeasured confounders. The clinical outcomes were simu-
lated as
S3 : R = 2H3 − H4 + A(H1 − H2 + X) + 6sign(H1)
+N(0, 1)
and
S4 : R = 1 + 2H1 + H2 + 0.5H3 + A(H2 + H21 + X − 1)
+6sign(H1) + N(0, 1),
where P(A = 1|H, X) = expit(1 + R(−1) − R(1) + 2X + H1) and
X is an unmeasured confounder (not included in any analysis in
any method) and R(−1), R(1) are potential outcomes under each
treatment.
Figure 2. Value comparison of four methods in the presence of unmeasured confounders. The numbers at the top of each subfigure are mean values.
After introducing unmeasured confounding, the true opti-
mal value function is 1.37 in S3 and 2.61 in S4. From Fig-
ure 2, we see that in S3 with a linear decision boundary, Q-
learning performs the best. Doubly robust M-learning has a
higher mean value than M-learning. Matching-based methods
have an advantage over AOL. Specifically, the value function of
ITR estimated by AOL has a large variability, especially when
the sample size is small. In S4 with nonlinear decision boundary,
two M-learnings much outperform AOL and Q-learning. In this
case, the unmeasured confounder has a greater impact on AOL
and Q-learning than M-learning.
We also examine M-learning with ordinal outcomes and
report results in supplementary materials A1. For linear deci-
sion boundary, since ordinal outcomes were generated by dis-
cretizing a continuous outcome, M-learning does not give an
advantage over Q-learning and AOL. For nonlinear boundary,
M-learning using matching function g(x) = 1 and g(x) = x
both achieves a higher value than Q-learning and AOL.
5. Application to EHRs to Learn Optimal Treatment
Sequence for T2D patients
We apply various methods to a large clinical data warehouse
(CDW) at New York Presbyterian Hospital (NYPH). NYPH
CDW is one of the earliest pioneer CDWs in the United States
developed 25 years ago, long before the wide adoption of EHRs
and informatics methods. The database encompasses about 4.5
million patients in the New York City population, making it a
useful data source for research and supports new research initia-
tives including eMERGE (Gottesman et al. 2013) and precision
medicine initiative. The details of the informatics technology
of NYPH CDW are described in Section A2 of supplementary
materials.
Our research goal is to optimize treatment sequence for T2D
patients based on their person-specific characteristics. Current
treatment guideline recommends metformin (MET) as the first
line treatment for T2D patients Diabetes Control and Compli-
cations Trial Research Group (1993). Literature reveals barriers
of timely insulin initiation in clinical practice when patients
do not achieve adequate glycemic control by using metformin
alone, and the optimal sequence of treatments for insulin ther-
apy versus second-line oral hypoglycemic agents (OHA) largely
remains unknown American Diabetes Association (2014). In
this work, we aim to estimate the optimal second-line treatment
for T2D patients who received MET as the first-line treatment
using real-world EHRs. Targeting the second-line treatments
(metformin + insulin versus metformin + SFU, where SFU refers
to oral agent sulfonylureas that includes glyburide and glipizide)
partially reduces confounding by indication, where treatment
uncertainty is present in real-world practice.
We excluded subjects with extreme baseline HbA1c values
(greater than 10%), and used a new-user cohort design (Ray
2003). Such design is often used in other studies of EHRs to
properly capture time-varying confounding and early treatment
responses. Specifically, the study design is illustrated in Figure 3.
Subjects who started a second-line treatment (new users)
are anchored at the treatment initiation (index date), and
Index Date: exposure to
Second-line treatments 
(insulin or 2nd line OHA), 
First-line treatment 
initiation (Metformin) Post-index HbA1c outcomes
Before 1st line
treatment initiation 
Figure 3. T2D EHR study design.
information before and after index date will be analyzed.
Subjects were included in the analyses if they had MET as
the first-line treatment, had insulin or SFU as the second-
line treatment, and had at least one observation post index
date. The median baseline period was around one year and the
median follow-up time post second-line treatment was about 18
months.
In Section A2 of supplementary materials, we describe details
of patient records extraction and feature extraction. We con-
structed patterns of laboratory measurements to handle chal-
lenges in the analyses of EHRs (e.g., confounding bias and
selection bias). Extracted features encompass information from
five domains (Figure A3.1 of supplementary materials): demo-
graphics, medication prescription, ICD diagnosis codes, labo-
ratory test values, and lab test measurement patterns. Propen-
sity scores were estimated using two distinct logistic regression
models for lab measurement pattern features and demographics
covariates. The matching step in M-learning was performed
using extracted features from lab test values, ICD counts, and
two propensity scores. In addition, to improve efficiency and
perform doubly robust matching, we also included a prognostic
score estimated from a linear regression model in the matching
step. Mahalanobis distance was the matching similarity measure
and one nearest-neighbor was used to select matched pairs.
To address selection bias in missing posttreatment outcomes,
we used the IPW method and constructed a logistic regression
model predicting whether a subject had any posttreatment lab
measure to compute the weights. To handle incompleteness in
features, imputation with chained equations was used Buuren
and Groothuis-Oudshoorn (2011).
Our final EHR data for learning optimal ITR consist of
740 patients, among whom 292 (39%) received insulin as the
second-line treatment while 448 (61%) received SFU. The out-
come is the HbA1c level (%) at a 6-month post second-line
treatment initiation estimated from a linear mixed effect model
with subject-specific random intercepts and random slopes.
Feature variables for learning optimal ITR include initial lab
test values (HbA1c, glucose, HDL, LDL, and BMI) and rate
of change of measurements before index date, demographic
variables, the cluster membership estimated from a subset of
features (online supplementary materials, Section A2, Figure
A3.2), counts of other nonglycemic medications and counts of
positive ICD diagnosis codes. Two-fold cross validation was
used to estimate the value function of fitted ITRs.
We divided our cohort to two groups according to the initial
HbA1c level (high baseline HbA1c group: >= 8.5 and low base-
line HbA1c group: < 8.5) and analyzed the groups separately to
further reduce patient heterogeneity. We compared the cross-
validated value function of doubly robust M-learning to non-
personalized universal rules, Q-learning, and AOL. In the rest
of this section, we refer doubly robust M-learning as M-learning
and AOL as O-learning for simplicity. The results are displayed
in Figure 4 and Table 1. In the low baseline group, there were
380 patients in total (240 received SFU, 140 received insulin).
For universal rules, the IPW-adjusted mean HbA1c level is 7.99
for those treated by SFU and is 8.05 for insulin. M-learning
achieves the best glycemic control among all methods (lowest
posttreatment HbA1c at 6 months) with a median and mean of
7.85 that is much lower than both universal rules. Q-learning
does not provide much improvement compared to universal
rules and its estimated posttreatment HbA1c is slightly smaller
than assigning SFU to all. In the high baseline group, there
were 152 patients who received insulin and 208 received SFU.
The universal rules for HbA1c level in SFU group is 8.90 and
in insulin group is 9.21. O-learning and M-learning have very
similar performance and both reduce the average posttreatment
HbA1c level to 8.57, again much lower than universal rules.
By examining M-learning in all patients using a linear kernel
in the low baseline group, we identified several features that
are most informative in determining the optimal treatment:
pretreatment rate of change of BMI, initial value of glucose
and LDL at the index date, co-medication count, patient cluster
membership, and race. These feature variables can be consid-
ered by health-care practitioner when recommending second-
line treatment for T2D patients. There were 263 (69%) of the
380 patients predicted to have “MET + SFU” as the optimal
choice and 117 (31%) with “MET + Insulin” as the optimal
choice. Of the 240 patients who were prescribed SFU as the
second-line treatment, majority of times (66%) medication was
also the predicted optimal treatment in terms of a lowering
HbA1c level. In contrast, among the 140 patients who were
prescribed insulin, only 36 (26%) were optimal. In the high
baseline group, the important features we identified are initial
value of HDL, age, sex, and patient cluster membership. 294
(82%) of the 360 patients were recommended to “MET + SFU.”
Of the 208 patients who were prescribed SFU, 168 (81%) also
had as the predicted optimal treatment. Among the 152 patients
who received insulin treatment, only 26 (17%) were optimal.
These results seem to suggest that some patients who received
insulin as the second-line treatment might be better treated with
SFU.
However, Bianchi and Del Prato (2011) suggested that tight
glycemic control need to be studied carefully in different group
of T2D patients to determine the balance of its negative and
positive effect and treatment personalization should be recom-
mended considering multiple factors such as risk of complica-
tions (e.g. cardiovascular events). Given a low rate of insulin
predicted to be optimal among patients who were treated with
insulin, we explored whether insulin could be prescribed based
on other considerations such as risk of complications in addition
to achieving glycemic control. We estimated the optimal ITR
that reduces major complications of T2D measured by three
ICD diagnosis counts including essential hypertension, hyper-
lipidemia, and hypercholesterolemia as ordinal outcomes (0,
1, 2, 3). M-learning was implemented with g(x) = x. The
results are displayed in Figure 5 and Table 2. In the low baseline
group, O-learning is moderately better than M-learning with an
average count of 0.72. Based on M-learning, SFU was predicted
to be optimal for 274 (72%) patients. Among patients who
indeed received SFU, 175 (73%) were predicted to be optimal
with regarding to reducing complications while 41 (29%) of the
patients who received insulin were predicted to be optimal. In
the high baseline group, M-learning performs the best with an
average value of 0.84. Further investigation shows that insulin
was predicted to be the optimal choice for 234 (65%) patients.
In this group, among 152 patients who indeed received insulin,
106 (70%) were predicted to be optimal with regard to reducing
Figure 4. Empirical value function of HbA1c in EHR data with 100 2-fold cross-validations (a low value is desirable).
Table 1. Cross-validated empirical value function for HbA1c.
High baseline group
Universal rules: MET + SFU: 8.90, MET + Insulin: 9.21
ITR Method Mean (std) Median (Q1, Q3)
Q-Learning 8.72 (0.124) 8.70 (8.64, 8.75)
O-learning 8.57 (0.038) 8.57 (8.54, 8.60)
M-Learning 8.57 (0.045) 8.57 (8.55, 8.59)
Low baseline group
Universal rules: MET + SFU: 7.99, MET + Insulin: 8.05
ITR Method Mean (std) Median (Q1, Q3)
Q-Learning 7.94 (0.083) 7.94 (7.88, 7.99)
O-learning 7.87 (0.061) 7.88 (7.83, 7.91)
M-Learning 7.85 (0.068) 7.85 (7.82, 7.90)
complications, while only 80 (38%) of the patients who received
SFU were predicted to be optimal.
In conclusion, the optimal ITRs outperform universal rules
in all groups for both outcomes. M-learning performs better
than Q-learning in all cases and better than O-learning in most
cases. In addition, the proportion of patients treated by insulin
and with insulin predicted to be optimal is higher when con-
sidering reducing complications as the outcome as compared
to controlling for HbA1c (from 17% to 70% in the high base-
line group). This result suggests that the rationale to prescribe
insulin might be also based on concerns of complications, espe-
cially when the baseline HbA1c is high (greater than 8.5%).
6. Discussion
We have proposed a machine learning approach based on
matching, M-learning, to estimate the optimal ITR from
observational data. We show that M-learning is a general
approach that includes O-learning and some of its derivatives
as special case and it satisfies Fisher consistency. A general
matching function is proposed to analyze continuous or discrete
outcomes where in some cases the objective function maximizes
a certain function of AUC. The choice of g(·) function provides
a flexible tool to weight outcome measures: g(x) = 1 gives the
most robust estimation which only concerns with the ranking
of outcomes; while other robust choices can prevent sensitivity
to outliers of Ri’s. Moreover, multivariate outcomes can be
incorporated in the M-learning framework by creating suitable
g function. The matching function g(x) can be selected from a
pool of nondecreasing functions to estimate the optimal ITRs
in a data-driven way, which may lead to a better posttreatment
response.
M-learning has a few advantages over O-learning or other
IPW-based methods. It does not rely on the validity of
propensity score models and no inverse weighting is involved.
Figure 5. Empirical value function of ICD diagnosis count in EHR data with 100 2-fold cross-validations (a low value is desirable).
Table 2. Cross-validated empirical value function for the number of major complications.
High baseline group
Universal rules: MET + SFU: 0.94, MET + Insulin: 0.89
ITR Method Mean (std) Median (Q1, Q3)
Q-Learning 0.88 (0.078) 0.88 (0.83, 0.93)
O-Learning 0.86 (0.050) 0.87 (0.83, 0.90)
M-Learning 0.84 (0.068) 0.83 (0.80, 0.88)
Low baseline group
Universal rules: MET + SFU: 0.89, MET + Insulin: 1.00
ITR Method Mean (std) Median (Q1, Q3)
Q-Learning 0.81 (0.063) 0.81 (0.76, 0.85)
O-Learning 0.72 (0.033) 0.72 (0.70, 0.74)
M-Learning 0.73 (0.032) 0.73 (0.71, 0.75)
Thus, instability can be avoided when there are extremely
small weights. The choice of Mi in M-learning is flexible
and can include a large suite of matching tools including
nearest neighbor, metrics defined on a dimension-reduced
space determined by propensity scores or prognostic scores,
yielding double robustness. For example, methods based on
greedy matching or optimal matching algorithm are available
to be implemented in M-learning. Different calipers can also
be specified for individual subject and hence allow more
“personalization.” This strategy will introduce more flexibility
but at the price of some computational complexity.
The choice of matching variables is important in M-learning.
The performance of M-learning may be affected by the presence
of high-dimensional features in the matching step. We suggest a
dimension reduction approach to match on a lower dimensional
space consisting of propensity score, prognostic score, and/or
cluster membership of patients. We also included some key
covariates as part of the matching criteria. A more general
practical guide during the matching step is: first, choose major
confounders according to domain knowledge or preliminary
studies to achieve covariates balance; second, construct several
propensity scores to reduce the dimensionality of the space of
matching covariates; and third, include prognostic scores in
order to improve robustness and efficiency. In the EHR analy-
sis here, we considered this general guideline and constructed
domain-wise propensity scores as well as prognostic scores, and
matching was performed based on these scores. Other variable
selection techniques can be considered, for example, to estimate
propensity and prognostic scores by penalized regression.
Single-stage M-learning can be generalized to multi-stage
setting by changing the value function V(D) to a corresponding
matching-based value function involving multiple stages and
applying the backward learning methods (Liu et al. 2018). In
each stage, M-learning will have the flexibility to choose differ-
ent matching function and matched features. Furthermore, an
extension to handle efficacy and safety outcomes (e.g., glycemic
control and risk of complications) simultaneously when learn-
ing ITR is desirable. Here, we only considered choosing between
two treatment options. M-learning is ready to be generalized
to more than two treatments by, for example, adopting one-
versus-one or one-versus-all strategies for multicategory learn-
ing (Allwein, Schapire, and Singer 2001). Lastly, our analyses
were restricted to EHRs from those who had at least one second-
line T2D treatment documented at a single academic medical
center. It would be of interest to examine the performance of
our methods on other EHR databases.
Supplementary Materials
The online supplementary materials contain additional simulations studies
and EHR data analyses results.
Appendix
Proof of Theorem 3.1. After some algebra, we can show that the
value function is equal to
E
[
I(f (H) > 0)
{
Ẽ[g(|̃R − R|)|R̃ − R| (R̃ − R)+|Ã = 1, H̃ = H]




I(f (H) ≤ 0)
{
Ẽ[g(|̃R − R|)|R̃ − R|
(R̃ − R)+|Ã = −1, H̃ = H] + Ẽ[g(|̃R − R|)|R̃ − R|
(R̃ − R)−|Ã = 1, H̃ = H]
}]
.
Hence, the optimal decision function, denoted by f ∗(H), should
have the same sign as
E
[{
Ẽ[g(|̃R − R|)|R̃ − R| (R̃ − R)+|Ã = 1, H̃ = H]






Ẽ[g(|̃R − R|)|R̃ − R| (R̃ − R)+|Ã = −1, H̃ = H]










E[g(|̃R − R|)|R̃ − R| (R̃ − R)|Ã = −1, H̃ = H]
∣∣∣H] .
In other words, if we define

g(r, h) = E
[
g(|R − r|)





|R − r| (R − r)|A = −1, H = h
]
,
then for any h in the support of H,




g(r, h)dF(r|H = h),
where F(r|H = h) is the distribution of R = r given H = h.
Proof of Theorem 3.2. For convenience of notation, we use ‖·‖n
to denote the norm in the RKHS and omit g in the definition of
the loss function, that is, denote Ln(f ; g) as Ln(f ). We use c to
denote a constant that is independent of n in the following proof.
The M-learning algorithm estimates the decision function f as
f̂ that minimizes (4), which can be rewritten as follows:
Ln(f ) ≡ Pn
⎡⎢⎢⎣
∫
I(d(H̃, H) < δn)φ(−f (H)
Asign(̃R − R))g(|̃R − R|)dP̃n∫
I(d(H̃, H) < δn)dP̃n
⎤⎥⎥⎦+ λn‖f ‖2n.
Here, P̃n and P̃ to be used later refer to the measures with
respect to an independent copy of random variables, (̃R, Ã, H̃).
We further define
Qn(R, A, H; f ) =
∫
I(d(H̃, H) < δn)φ(−f (H)
Asign(̃R − R))g(|̃R − R|)dP̃n∫
I(d(H̃, H) < δn)dP̃n
and
Q(R, A, H; f )
= Ẽ
[
φ(−f (H)Asign(̃R − R))g(|̃R − R|)
∣∣∣H̃ = H].
Clearly, Ln(f ) = PnQn(R, A, H; f ) + λn‖f ‖2n.
Let Lφ(f ) = E[Q(R, A, H; f )]. From the general property of
the weighted hinge-loss as shown in Theorem 3.2 of Zhao et al.
(2012), we have
V(f ∗; g) − V (̂f ; g) ≤ c
{
Lφ(̂f ) − Lφ(f ∗)
}
.
Therefore, it is sufficient to obtain a bound for the right-hand
side. First, since Lφn(̂f ) ≤ Lφn(0), we obtain λn‖̂f ‖2n ≤ 1. Let
f0n be the minimizer of Lφ(f )+λn‖f ‖2n over f ∈ HK . Therefore,
Lφ(̂f ) − Lφ(f ∗)
≤ E
[
Q(R, A, H; f̂ )
]
− E [Q(R, A, H; f0n)]
+E [Q(R, A, H; f0n)]− V(f ∗)
≤ −(Pn − P)
[








Q(R, A, H; f0n)
]
+E [Q(R, A, H; f0n)]− V(f ∗)
≤ sup
f :‖f ‖n≤λ−1/2n
∣∣∣(Pn − P)Q(R, A, H; f )∣∣∣
+Pn
[




Q(R, A, H; f0n) − Qn(R, A, H; f0n)
]
+Ln(̂f ) − λn‖̂f ‖2n − Ln(f0n)
+E [Q(R, A, H; f0n)]+ λn‖f0n‖2n − V(f ∗)
≤ sup
f :‖f ‖n≤λ−1/2n
∣∣∣(Pn − P)Q(R, A, H; f )∣∣∣ (I)
+ sup
R,A,H
∣∣∣Q(R, A, H; f̂ ) − Qn(R, A, H; f̂ )∣∣∣ (II)
+ sup
R,A,H
∣∣∣Q(R, A, H; f0n) − Qn(R, A, H; f0n)∣∣∣ (III)
+E [Q(R, A, H; f0n)]+ λn‖f0n‖2n − V(f ∗). (IV)
We refer the terms in the right-hand side as (I), (II), (III), and
(IV) in turn.
For term (I), we compute the bracket covering number of
some finite balls in HK . First, from Theorem 3.1 in Steinwart
and Scovel (2007), the entropy number for the unit ball in HK ,
denoted by On, satisfies
logN (ε,On, ‖ · ‖∞) ≤ cσ−(1−p/4)dn ε−p
for a constant c depending on p and d, so it yields




f : f ∈ Hσn , ‖f ‖n ≤ λ−1/2n )
}
,
‖ · ‖L2(P)) ≤ cσ−(1−p/4)dn ε−p(1/λn)p/2.
Note that Q(R, A, H; f ) is Lipschitz continuous with respect to f
in the sense that∣∣∣Q(R, A, H; f1) − Q(R, A, H; f2)∣∣∣ ≤ c|f1(H) − f2(H)|,
where c is a constant bounding g(|R − R̃|). Therefore, we obtain
logN[](ε,
{
Q(R, A, H; f ) : ‖f ‖n ≤ λ−1/2n
}
,
‖ · ‖L2(P)) ≤ cσ−(1−p/4)dn ε−p/λp/2n .
According to Theorem 2.14.2 in Van Der Vaart and Wellner
















= Op(1)n−1/2σ−(1/2−p/8)dn /λp/4n .
For term (II), since ‖̂f ‖n ≤ λ−1/2n , Theorem 4.48 in Steinwart
and Christmann (2008), implies that f̂ is differentiable with
derivative bounded by cσ−1n ‖̂f ‖n = cσ−1/2n λ−1/2n . Using the
uniform convergence rate result for nearest-neighbor estimators
(Devroye, Györfi, and Lugosi 2013; Jiang 2017) and assumptions




)1/p +√p log n
mn
⎤⎦ .
The same bound holds for term (III). Finally, the last term is the
approximation error as defined in Steinwart and Christmann
(2008) but with a different definition of the loss function as
Q(R, A, H; f ). We can follow exactly the same argument in The-
orem 2.7 of Steinwart and Christmann (2008) to obtain its upper
bound as c(σ−pn λn + σαpn ) for any positive α.
In conclusion, we have shown














⎫⎬⎭+ σ−pn λn + σαpn
⎤⎦ .
By choosing σn = λ1/p(1+α)n , we obtain the result in Theorem 2.
As a remark, the tail probability, P(|V(f ∗; g) − V(f̂ ; g)| ≥ t)
where t > 0, can also be obtained under similar arguments.
Theorem 3.2 provides a stochastic bound for term (I) in the
appendix. One can obtain the bound of the tail probability for
this term using the tail bound for empirical processes (Chapter
2.14, Van Der Vaart and Wellner 1996). Then the tail probability,
P(|V(f ∗; g) − V(f̂ ; g)| ≥ t), will follow.
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